HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Carbidopa

HCID 34359
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
28860-95-9
Standard SMILES
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O
InChIKey
TZFNLOMSOLWIDK-JTQLQIEISA-N
Molecular formula
C10H14N2O4
Average molar mass
226.23 g/mol
Monoisotopic mass
226.09535693

Overview

Carbidopa (anhydrous) is 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa. It has a role as an antiparkinson drug, a dopaminergic agent and an EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor. It is a member of hydrazines, a monocarboxylic acid and a member of catechols.

Names & identifiers

Preferred name
Carbidopa
IUPAC
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
English name
S-(-)-Carbidopa
Molecular formula
C10H14N2O4
Molecular weight
226.23

Names & synonyms

carbidopa28860-95-9LodosynCarbidopa anhydrousN-Aminomethyldopa(S)-(-)-carbidopaalpha-MethyldopahydrazineCarbidopumL-alpha-Methyldopahydrazine(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acidCarbidopa (anhydrous)(S)-carbidopa
Show more names
S(-)-CARBIDOPACarbidopa-d3mk486KINSONL-3-(3,4CARBIDOPA EDMFCarbidopa MonomerCARBIDOPAANHYDROUS
MK 486L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acidMK-486DTXSID4022735(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acidKR87B45RGH(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acidDTXCID502735

Database identifiers

CAS
28860-95-9、38821-49-7
PubChem CID
34359
DTXSID
DTXSID4022735
ChEMBL
CHEMBL1200748、CHEMBL1201236

Properties

Computed structural propertiesFilling in

XLogP
-2.2
Topological polar surface area
116 Ų
Hydrogen bond donors
5
Hydrogen bond acceptors
6
Rotatable bonds
4
Heavy atoms
16
Formal charge
0
Complexity
261

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Used in Switzerland

LogP-1.9
Human Drugs · 3 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Boiling PointDecomposes
Melting Point · 2 items

203-208 °C

203 - 205 °C

Physical DescriptionSolid
Dissociation Constants2.3
Collision Cross Section · 2 items

142.4 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

143.39 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 6 items

This chemical does not meet GHS hazard criteria for 2.7% (2 of 75) of reports.

Danger

H315 (82.7%): Causes skin irritation [Warning Skin corrosion/irritation]

P203, P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 75 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Warning

Hazard information

Regulatory InformationREACH registered substance: Carbidopa (EC: 249-271-9)
Hazard Classes and Categories · 2 items

Skin Irrit. 2 (82.7%)

Muta. 2 (100%)

Toxicology

Adverse Effects · 1 item

Because of the irreversible binding of AADC, carbidopa can decrease or deplete peripheral levels of serotonin, dopamine, norepinephrine, and epinephrine. Additionally, research has demonstrated that the irreversible binding of PLP causes nutritional deficiencies in vitamins B3 and B6. Specific carbidopa-induced dyskinesias, including “facial twitching and head bobbing,” have also been described.

Toxicity Summary · 1 item

There is little data to suggest a possibility for or symptoms of carbidopa toxicity. However, reported data indicate that carbidopa/levodopa intestinal gel infusion can cause significant damage to small nerve fibers leading to pain and sensory discomfort.

Chemistry & industry

Pharmacology

Protein BindingIt is widely accepted that the protein binding of carbidopa is 76%. However, more studies are required or the presentation of the source of this information.
Pharmacodynamics · 1 item

When mixed with [levodopa], carbidopa inhibits the peripheral conversion of [levodopa] to dopamine and the decarboxylation of [oxitriptan] to serotonin by aromatic L-amino acid decarboxylase. This results in an increased amount of [levodopa] and [oxitriptan] available for transport to the central nervous system. Carbidopa also inhibits the metabolism of [levodopa] in the GI tract, thus, increasing the bioavailability of [levodopa]. The presence of additional units of circulating [levodopa] can increase the effectiveness of the still functional dopaminergic neurons and it has been shown to alleviate symptoms for a time. The action of carbidopa is very important as [levodopa] is able to cross the blood-brain barrier while dopamine cannot. Hence the administration of carbidopa is essential to prevent the transformation of external [levodopa] to dopamine before reaching the main action site in the brain. The coadministration of carbidopa with [levodopa] has been shown to increase the half-life of [levodopa] more than 1.5 times while increasing the plasma level and decreasing clearance. The combination therapy has also shown an increase of the recovery of [levodopa] in urine instead of dopamine which proves a reduced metabolism. This effect has been highly observed by a significant reduction in [levodopa] requirements and a significant reduction in the presence of side effects such as nausea. It has been observed that the effect of carbidopa is not dose-dependent.

Mechanism of Action · 1 item

Carbidopa is an inhibitor of the DDC which in order, inhibits the peripheral metabolism of levodopa. DDC is very important in the biosynthesis of L-tryptophan to serotonin and the modification of L-DOPA to dopamine. DDC can be found in the body periphery and in the blood-brain barrier. The action of carbidopa is focused on peripheral DDC as this drug cannot cross the blood-brain barrier. Hence, it will prevent the metabolism of [levodopa] in the periphery but it will not have any activity on the generation of dopamine in the brain.

Biological Half-LifeThe reported half-life of carbidopa is of approximately 107 minutes.

Related reactions

6 records
New reaction record
HRID 452338 reaction equation
HRID 452338As product
HRID 452339 reaction equation
HRID 452339As reactant
HRID 2212438 reaction equation
HRID 2212438As reactant
HRID 2212446 reaction equation
HRID 2212446As reactant
HRID 2212452 reaction equation
HRID 2212452As reactant
HRID 2242762 reaction equation
HRID 2242762As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
ChEBI
CHEBI:39585
UNII
KR87B45RGH
EC Number
249-271-9、657-445-4
Nikkaji
J17.160C

Physicochemical properties

Melting point
203 · 203-205° (dec); mp 208°
alpha
-17.3 ° · D -17.3° (methanol)
Boiling point
367.84 °C · 367.84°C (rough estimate)
Density
1.2616 · 1.2616 (rough estimate)
refractive index
1.5 · 1.5000 (estimate)
storage temp.
-20 °C · -20°C
solubility
DMSO (Slightly), Methanol (Slightly)
pka
3.4 · 3.40±0.14(Predicted)
form
powder
color
White to Off-White
Stability
Unstable in Solution
InChI
InChI=1/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/s3
InChIKey
TZFNLOMSOLWIDK-JQHDBZEONA-N
SMILES
[C@@](C)(NN)(C(=O)O)CC1C=CC(O)=C(O)C=1 |&1:0,r|
CAS DataBase Reference
28860 · 28860-95-9(CAS DataBase Reference)
FDA UNII
87 B45RGH · KR87B45RGH
UNSPSC Code
12352202 · 12352202
NACRES
77 · NA.77
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302-H315-H319-H335
Precautionary statements
261 · P261-P305+P351+P338
PPE
95 · Eyeshields, Gloves, type N95 (US)
WGK Germany
3 · 3
RTECS
5298000 · MW5298000
Storage Class
11 · 11 - Combustible Solids
REACH Registrations
Active
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Carbidopa

Ambiguous-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

EPA Human Health Benchmarks for Pharmaceuticals · 6 items

Carbidopa

1.6

6.9

Most patients respond to a 1:10 proportion of carbidopa and levodopa, provided the daily dosage of carbidopa is 70 mg or more a day.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 70 mg/day, Lowest Therapeutic Dose (LTD): 0.9 mg/kg-day, and Screening Dose: 0.0003 mg/kg-day.

2-Jul-20

Safety data

PPE
Eyeshields, Gloves, type N95 (US)
wgk
3
rtecs
MW5298000
Signal word
Warning
Symbol(GHS)
GHS07
Storage Class
11 - Combustible Solids
Hazard statements
H302-H315-H319-H335
REACH Registrations
Active
Precautionary statements
P261-P305+P351+P338
Metabolism/Metabolites · 1 item

The loss of the hydrazine functional group (probably as molecular nitrogen) represents the major metabolic pathway for carbidopa. There are several metabolites of carbidopa metabolism including 3-(3,4-dihydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methylpropionic acid, 3-(3-hydroxyphenyl)-2-methylpropionic acid, 3-(4-hydroxy-3-methoxyphenyl)-2-methyllactic acid, 3-(3-hydroxyphenyl)-2-methyllactic acid, and 3,4-dihydroxyphenylacetone (1,2).

FDA Pharmacological Classification · 5 items

MNX7R8C5VO

CARBIDOPA

Established Pharmacologic Class [EPC] - Aromatic Amino Acid Decarboxylation Inhibitor

Mechanisms of Action [MoA] - DOPA Decarboxylase Inhibitors

Carbidopa is an Aromatic Amino Acid Decarboxylation Inhibitor. The mechanism of action of carbidopa is as a DOPA Decarboxylase Inhibitor.

MeSH Pharmacological Classification · 3 items

Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.

Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.

Compounds and drugs that block or inhibit the enzymatic action of AROMATIC AMINO ACID DECARBOXYLASES. Pharmaceutical agents in this category are used in conjunction with LEVODOPA in order to slow its metabolism.

Absorption, Distribution and Excretion · 4 items

When [levodopa]/carbidopa is administered orally, 40-70% of the administered dose is absorbed. Once absorbed, carbidopa shows bioavailability of 58%. A maximum concentration of 0.085 mcg/ml was achieved after 143 min with an AUC of 19.28 mcg.min/ml.

In animal studies, 66% of the administered dose of carbidopa was eliminated via the urine while 11% was found in feces. These studies were performed in humans and it was observed a urine excretion covering 50% of the administered dose.

The volume of distribution reported for the combination therapy of carbidopa/[levodopa] is of 3.6 L/kg. However, carbidopa is widely distributed in the tissues, except in the brain. After one hour, carbidopa is found mainly in the kidney, lungs, small intestine and liver.

The reported clearance rate for the combination therapy of [levodopa]/carbidopa is 51.7 L/h.

Uses & manufacturing

UsesUse (kg; approx.) in Germany (2009): >5000
Use ClassificationPharmaceuticals
Applications · 3 items

Usesin combinaison with levodopa as antiparkinsonian;inhibits aromatic-L-amino-acid decarboxylase (DOPA Decarboxylase or DDC)

Uses(S)-(-)-Carbidopa is a peripheral decarboxylase inhibitor that is commonly used in combination with L-DOPA (D533751) for treatment of Parkinsonism. S(-)-Carbidopa ( has also been shown to prolong the elimination half-life of L-DOPA from blood plasma and skeletal muscle.

General DescriptionCarbidopa is used for treating restless legs (RL) syndrome and periodic leg movements in sleep (PLMS). Carbidopa along with levodopa is used to treat Parkinson′s disease.

Upstream & downstream products

Upstream raw materials

4-VinylphenolSodium bisulfite water solutionDiethylamineSodium bisulfite4-HydroxyphenylacetoneButylamineSodium cyanideVanillinNitroethanePOTASSIUM CYANIDEHydrochloric acidIronHydrazine hydrateHydrogen bromideAcetic acid
Additional notes · 1 item

DefinitionChEBI: 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversi n of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.